• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在达到 MRD 阴性缓解后出现可测量残留疾病（MRD）复发的急性髓系白血病患者中，治疗干预的临床结果和影响。

Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission.

机构信息

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

出版信息

Am J Hematol. 2022 Nov;97(11):E408-E411. doi: 10.1002/ajh.26698. Epub 2022 Sep 8.

DOI:10.1002/ajh.26698
PMID:36054774
Abstract

Recurrence of MRD in AML is associated with imminent relapse unless intervened upon. Change in chemotherapy regimen and/or immediate transplant improve outcomes.

摘要

AML 患者的 MRD 复发与即将发生的疾病复发相关，除非进行干预。改变化疗方案和/或立即进行移植可以改善预后。

相似文献

1
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission.在达到 MRD 阴性缓解后出现可测量残留疾病（MRD）复发的急性髓系白血病患者中，治疗干预的临床结果和影响。
Am J Hematol. 2022 Nov;97(11):E408-E411. doi: 10.1002/ajh.26698. Epub 2022 Sep 8.
2
Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.可测量残留疾病、调理方案强度和年龄可预测首次缓解的急性髓系白血病患者接受异基因造血细胞移植的结果：欧洲血液和骨髓移植学会急性白血病工作组对 2292 例患者的注册分析。
Am J Hematol. 2018 Sep;93(9):1142-1152. doi: 10.1002/ajh.25211. Epub 2018 Aug 15.
3
The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.无 FLT3-ITD、NPM1 和双等位 CEBPA 突变的中危急性髓系白血病微小残留病检测对预后和缓解后治疗选择的影响。
Hematology. 2021 Dec;26(1):179-185. doi: 10.1080/16078454.2021.1880753.
4
The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia.可测量残留疾病（MRD）在血液系统恶性肿瘤（以急性白血病为主）造血干细胞移植中的作用。
Int J Mol Sci. 2019 Oct 28;20(21):5362. doi: 10.3390/ijms20215362.
5
Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors.强调急性髓系白血病危险因素中可测量残留疾病的预后重要性。
Turk J Haematol. 2021 Jun 1;38(2):111-118. doi: 10.4274/tjh.galenos.2020.2020.0157. Epub 2020 Oct 28.
6
NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia.基于 NPM1 突变的缓解后两疗程治疗后微小残留病评估是急性髓系白血病预后的有价值的临床预测指标。
Int J Hematol. 2022 Aug;116(2):199-214. doi: 10.1007/s12185-022-03328-6. Epub 2022 Apr 4.
7
[Clinical Study on Dynamic Detection of Minimal Residual Disease in Acute Myeloid Leukemia by Multiparameter Flow Cytometry].多参数流式细胞术动态检测急性髓系白血病微小残留病的临床研究
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Jun;30(3):737-743. doi: 10.19746/j.cnki.issn.1009-2137.2022.03.012.
8
Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.流式细胞术检测微小残留病对急性髓系白血病患者异基因造血干细胞移植前后的预后影响
Eur J Haematol. 2014 Sep;93(3):239-46. doi: 10.1111/ejh.12336. Epub 2014 Apr 29.
9
Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.多基因可测量残留病评估改善自体造血细胞移植中急性髓系白血病的复发风险分层
Biol Blood Marrow Transplant. 2016 Nov;22(11):1974-1982. doi: 10.1016/j.bbmt.2016.08.014. Epub 2016 Aug 17.
10
Interferon-α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study.干扰素-α 对异基因造血干细胞移植后 t(8;21) 急性髓系白血病患者微小残留病的治疗有效：一项前瞻性登记研究的结果。
Oncologist. 2018 Nov;23(11):1349-1357. doi: 10.1634/theoncologist.2017-0692. Epub 2018 Aug 3.

引用本文的文献

1
Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia.可测量残留病在接受异基因造血细胞移植治疗急性髓系白血病患者中的意义
Cells. 2025 Feb 15;14(4):290. doi: 10.3390/cells14040290.
2
Acute myeloid leukemia management and research in 2025.2025年急性髓系白血病的管理与研究
CA Cancer J Clin. 2025 Jan-Feb;75(1):46-67. doi: 10.3322/caac.21873. Epub 2024 Dec 10.
3
Measurable residual disease monitoring in AML: Prospects for therapeutic decision-making and new drug development.
急性髓系白血病中可测量残留病监测：治疗决策与新药研发的前景
Am J Hematol. 2025 Mar;100 Suppl 2(Suppl 2):5-15. doi: 10.1002/ajh.27482. Epub 2024 Sep 25.
4
Current status and research directions in acute myeloid leukemia.急性髓细胞白血病的现状与研究方向。
Blood Cancer J. 2024 Sep 19;14(1):163. doi: 10.1038/s41408-024-01143-2.
5
Detection methods and prognosis implications of measurable residual disease in acute myeloid leukemia.急性髓系白血病中可测量残留病的检测方法及预后意义
Ann Hematol. 2024 Dec;103(12):4869-4881. doi: 10.1007/s00277-024-06008-z. Epub 2024 Sep 16.
6
A chest CT-based nomogram for predicting survival in acute myeloid leukemia.基于胸部 CT 的急性髓系白血病生存预测列线图。
BMC Cancer. 2024 Apr 12;24(1):458. doi: 10.1186/s12885-024-12188-8.
7
Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions.急性髓系白血病中可测量残留病的检测：当前挑战与未来方向
Biomedicines. 2024 Mar 7;12(3):599. doi: 10.3390/biomedicines12030599.
8
Optimal Post-Remission Consolidation Therapy in Patients with AML.急性髓系白血病患者缓解后巩固治疗的最佳选择。
Acta Haematol. 2024;147(2):147-158. doi: 10.1159/000535457. Epub 2023 Nov 26.
9
Standardization of Molecular MRD Levels in AML Using an Integral Vector Bearing ABL and the Mutation of Interest.使用携带ABL和感兴趣突变的整合载体对急性髓系白血病分子微小残留病水平进行标准化。
Cancers (Basel). 2023 Nov 10;15(22):5360. doi: 10.3390/cancers15225360.
10
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML.FLT3 抑制剂作为 MRD 指导下的挽救治疗用于 FLT3 突变 AML 的分子学失败。
Leukemia. 2023 Oct;37(10):2066-2072. doi: 10.1038/s41375-023-01994-x. Epub 2023 Aug 9.